{"id":"lais","safety":{"commonSideEffects":[{"rate":null,"effect":"Elevated intraocular pressure"},{"rate":null,"effect":"Cataract progression"},{"rate":null,"effect":"Corneal edema"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LAIS (Levotas Aqueous Implant System) is a biodegradable intracameral implant designed to provide prolonged corticosteroid delivery to the anterior segment of the eye. By releasing dexamethasone directly into the aqueous humor over an extended period, it maintains therapeutic anti-inflammatory levels while minimizing systemic exposure and the need for frequent topical dosing.","oneSentence":"LAIS is a sustained-release intracameral steroid injection that delivers dexamethasone directly into the anterior chamber of the eye to reduce inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:51:33.761Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Post-operative inflammation following cataract surgery"},{"name":"Anterior uveitis"}]},"trialDetails":[{"nctId":"NCT03919994","phase":"","title":"Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2019-03-28","conditions":"Schizophrenia","enrollment":338},{"nctId":"NCT02609581","phase":"","title":"Tolerability of SLIT With LAIS® Mites Allergoid Tablets","status":"COMPLETED","sponsor":"University Hospital of Cologne","startDate":"2015-12-01","conditions":"Allergic Rhinitis","enrollment":192},{"nctId":"NCT02553590","phase":"","title":"Tolerability of SLIT With LAIS® 2-Tree Allergoid Tablets","status":"COMPLETED","sponsor":"University Hospital of Cologne","startDate":"2015-01","conditions":"Allergic Rhinitis","enrollment":160},{"nctId":"NCT02277483","phase":"PHASE4","title":"Efficacy and Safety of LAIS® Mites Sublingual Tablets","status":"UNKNOWN","sponsor":"Ajou University School of Medicine","startDate":"2014-10","conditions":"Allergic Conditions","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":671,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["active treatment"],"phase":"marketed","status":"active","brandName":"LAIS®","genericName":"LAIS®","companyName":"Ajou University School of Medicine","companyId":"ajou-university-school-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LAIS is a sustained-release intracameral steroid injection that delivers dexamethasone directly into the anterior chamber of the eye to reduce inflammation. Used for Post-operative inflammation following cataract surgery, Anterior uveitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}